DI-004 Evaluation of the use of pazopanib in a tertiary-level hospital

• Published in: European journal of hospital pharmacy. Science and practice Vol. 21; no. Suppl 1; p. A71
• Main Authors: Alonso Castro, V, Escudero Vilaplana, BM, Folguera Olias, C, Diez Alcantara, A, Torralba Arranz, A
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2014
• Subjects: Kidney cancer; Kinases; Metastasis
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2013-000436.175

Background Pazopanib is a protein kinase inhibitor. It is indicated in adults for the treatment of advanced Renal Cell Carcinoma (RCC) and the treatment of patients with particular subtypes of advanced Soft Tissue Sarcoma (STS). Purpose To evaluate the effectiveness and safety of pazopanib in a tertiary care hospital. Materials and methods Descriptive observational study of the use of pazopanib since February 2011. The following data were recorded in the medical history in the Selene application (medical history software): sex, age at which the treatment was initiated, pathology, indication, line of treatment, prescribing service and adverse reactions. Results 19 patients were analysed (57% male), with an average age of starting treatment of 54 years (24–80 years). 16 of them met the approved criteria: 10 metastatic RCC (6 were first line and 4 second line) and 6 STSs (3 second line, 2 third line and 1 fourth line). In adddition, 2 were off-label: 2 metastatic thyroid carcinoma (second line) and 1 metastatic pancreatic adenocarcinoma (third line). Prescriber services were oncology (16 patients), endocrinology (2) and urology (1). Only 7 patients continue on treatment. The average duration of treatment was 244 days (14–650 days) and the reasons for dropout were: tumour progression (6), intolerance to treatment (5), no available data (1). 11 patients presented adverse reactions. Most were: asthenia (3), weight loss (2), diarrhoea (3), nausea (1), esophagitis (1), muscle pain (2), hand-foot syndrome (1), hypertension (2), ALT/AST elevation (3), impaired renal function (2), hypokalaemia (1), visual loss (1), lymphopenia (1), anaemia (1), skin graft necrosis (1). Conclusions The average duration of the treatment (244 days) and the fact that seven patients continue treatment reveals that pazopanib is effective in controlling disease progression. Oral administration and the fact that most adverse effects recorded are mild provides advantages over other therapeutic alternatives. No conflict of interest.